Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical application of artabsin A and B as alpha-glucosidase inhibitors and accordingly as materials for preparing antidiabetic drugs

A technology of glucosidase and galactone, applied in the field of medicine

Active Publication Date: 2020-02-07
南京泓纬医药科技有限公司
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no report that enigninactone A and B are used as α-glucosidase inhibitors and then used to prepare hypoglycemic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of artabsin A and B as alpha-glucosidase inhibitors and accordingly as materials for preparing antidiabetic drugs
  • Medical application of artabsin A and B as alpha-glucosidase inhibitors and accordingly as materials for preparing antidiabetic drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] 1. Test materials

[0019] α-glucosidase (yeast) was purchased from Shanghai Jingke Chemical Technology Co., Ltd.

[0020] p-nitrobenzene-β-D-galactopyranoside and DMSO were analytically pure.

[0021] The purity of acarbose, enininactone A and enininactone B is not less than 98%.

[0022] The brand of 96-well plate is Corning.

[0023] 2. Test method

[0024] According to the method disclosed in the literature (Study on lanolin-type triterpenoids in Chizhi and its α-glucosidase inhibitory activity, Chinese herbal medicine, 2017):

[0025] Solution preparation: take α-glucosidase to prepare 0.2U / mL enzyme solution; take p-nitrophenyl-β-D-galactopyranoside (PNPG) to prepare 2.5mM PNPG solution; prepare pH6 according to conventional formula .8 potassium phosphate buffer solution.

[0026] The inhibition test was carried out in a 96-well plate, and the 140 μL potassium phosphate buffer solution (pH6.8) reaction system in each well contained 20 μL of 0.2 U / mL α-glucosi...

Embodiment 2

[0033] A hypoglycemic tablet, the formula of which comprises 10 mg of cyanolactone A or 10 mg of cyanolactone B, 90 g of starch, and 3 g of magnesium stearate.

[0034] Preparation process: Take enigninactone A or enigninactone B, add starch and magnesium stearate, mix evenly, granulate, dry, and compress into tablets.

Embodiment 3

[0036] A hypoglycemic capsule, the formula of which comprises 10 mg of enigninactone A or enigninactone B, 90 g of starch and 3 g of magnesium stearate.

[0037] Preparation process: Take enigninactone A or enigninactone B, add starch and magnesium stearate, mix evenly, granulate, dry, and pack into capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses medical application of artabsin A and B as alpha-glucosidase inhibitors and accordingly as materials for preparing antidiabetic drugs. Research results of the embodiment show that the artabsin A and B have significant inhibition effects on alpha-glucosidase, the inhibition intensities of the artabsin A and B are higher than that of a positive drug acarbose, and thus both the artabsin A and B can be used for preparing the antidiabetic drugs. Furthermore, compared with the artabsin A, the artabsin B has the significantly higher inhibition intensity on the alpha-glucosidase, the inhibition intensity of the artabsin B is 15 times or more that of the artabsin A, and thus the artabsin B is an antidiabetic drug with better prospects.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the medical use of cylindrolactone A and B as an α-glucosidase inhibitor and further used to prepare hypoglycemic drugs. Background technique [0002] Enininactone A and eninininactone B are a pair of isomers, the difference is only in one connection -OH and -CH 3 The chirality of the carbon atom is different, and the chemical structural formulas of cinnamate A and B are as follows: [0003] [0004] Starch in food is digested by salivary enzymes in the mouth, acid in the stomach, and tryptic amylase in the digestive tract into oligosaccharides, disaccharides, and trisaccharides containing a small number of glucose molecules, and finally passes through the brush border membrane of the small intestinal villi epithelial cells Existing membrane-bound enzymes, maltotriose and disaccharide hydrolase (α-glucosidase, sucrase, maltase), etc. are decomposed into monosaccharides, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61P3/10
CPCA61K31/365A61P3/10
Inventor 朱阳晨赵玲
Owner 南京泓纬医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com